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Abstract
Purpose. The prognosis for patients with Ewing’s tumours who have metastases at presentation or who are refractory to
standard chemotherapy regimens remains poor. There is therefore a need to evaluate the role of new agents. This report
describestheinitialresultsofaprospectivephaseIItrialofdocetaxelinpatientswithprogressiveorrefractoryEwing’stumours.
Patients and methods. Fourteen patients with Ewing’s tumours who had all relapsed or progressed after treatment with
multi-drugcytotoxictherapyweretreatedwithdocetaxel100mg/m
2infusedover1h,threeweeklyforamaximumofsixcycles.
Nine patients received granulocyte colony-stimulating factor with all cycles.
Results. A partial response was observed in one patient and stable disease in two. The remaining patients progressed on
treatment. The major toxicity was myelosuppression and infection with 36% patients experiencing grade 3 or 4 neutropenia
and/or infection.
Conclusion. Docetaxel appears to have some activity in Ewing’s tumours even in heavily pre-treated patients. Further evalua-
tion of its efficacy at an earlier stage of the disease is warranted.
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Introduction
The Ewing’s family of tumours includes Ewing’s
sarcoma of bone and extraosseous sites, primitive
neuroectodermal tumours (PNET) and Askin’s
tumours. All are characterised morphologically as
small blue round malignant cells which appear to
derive from the same primordial stem cell, differing
only in the degree of neural differentiation.
1 These
tumours occur most commonly in the second decade
of life and have an annual incidence of 0.6/million
population.
2
Approximately 20–30% of patients have overt
metastases at presentation, yet, before the introduc-
tion of systemic chemotherapy, 90% ultimately died
fromm etastatic disease.
3 With aggressive cytotoxic
chemotherapy survival rates of up to 70% are now
reported in localised disease.
4,5 indicating both that
the tumour is chemosensitive and that it should be
regarded as a systemic disease. Standard treatment
now comprises multi-drug chemotherapy including
agents such as vincristine, ifosfamide, cyclopho-
sphamide, etoposide, actinomycin D and doxorubi-
cin combined with either radiotherapy or surgery or
both to the primary site.
5–7 In metastatic disease the
prognosis is less favourable with disease-free survival
rates ranging between 10 and 20%.
8,9 The site of
metastatic disease is an important determinant and
those with pulmonary disease have a more favourable
outlook than those with bone or bone marrow
disease, while those with both have a cure rate of
less than 15%.
10 In this poor prognostic group the
role of high dose chemotherapy has shown some
promise
11 and is being further evaluated in prospec-
tive randomised trials.
Recurrent or progressive disease carries a very
grave prognosis, particularly if progression occurs on
treatment or after a short disease-free interval. In this
setting, evaluation of new agents in a phase II study is
warranted.
Docetaxel is a semi-synthetic drug derived from a
precursor extracted fromthe needles of Taxus
baccata.
12 In common with other taxanes such as
paclitaxel, docetaxel promotes microtubule assembly
and inhibits disassembly thereby causing cellular
growth arrest. This class of drug has shown useful
activity in a variety of epithelial solid tumours
including breast
13–15and ovarian cancer.
16,17
However, response rates in soft tissue sarcoma and
bone tumours have been generally disappointing
18–20
even when used as first line treatment.
21 Ewing’s
tumours are relatively chemosensitive by comparison
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DOI: 10.1080/1357714031000114192with other sarcomas yet no study has specifically
examined their response to taxanes. We have there-
fore performed a prospective phase II study to deter-
mine the clinical efficacy and toxicity of docetaxel in
relapsed or refractory Ewing’s tumours.
Patients and methods
Eligibility and evaluation criteria
Patients between the ages of 14 and 70 years of age
with histologically proven Ewing’s tumours were
enrolled prospectively into this study, which had
been approved by the local ethics committee. All
patients had received ‘standard’ chemotherapy and
either progressed or relapsed. Further eligibility
criteria included clinically or radiologically assessable
disease (measurable in two dimensions) or evaluable
disease (measurable in one dimension), WHO per-
formancestatus  3and alifeexpectancygreaterthan
8 weeks. Blood laboratory requirements at entry
included an absolute neutrophil count of  1.5 
10
9/l, platelets  100 10
9/l, serumbilirubin  1 
upper normal limit (UNL), AST and/or ALT
 1.5  UNL, alkaline phosphatase  2.5  UNL
(unless bone metastases were present in the absence
of liver metastases) and a serum creatinine  1.5 
UNL. Other exclusion criteria included symptomatic
peripheral neuropathy   grade 2 by NCI common
toxicity criteria, a history of severe hypersensitivity to
polysorbate 80 or contraindication to the use of
steroids.
Patients provided written consent according to the
local ethics committee requirements and, in the case
of minors under the age of 18, consent was provided
both by the child and the parents.
Prior to entry a full medical history and physical
examination was performed including an assessment
of performance status, residual toxicity following
prior treatments and clinical tumour measurements.
The relevant blood tests were also performed, as
were a chest X-ray, a technetiumbone scan, a
pulmonary CT scan and, if appropriate, imaging of
the primary site by plain X-ray and CT or MRI scan.
Prior to each treatment the clinical history was
recorded including symptoms and toxicities follow-
ing the previous treatment, weight and performance
status. Serumbilirubin, AST, ALT and alkaline
phosphatase were analysed before each cycle of
treatment and full blood count was performed
before treatment and on days 8 and 15 after cycles
1and2.Imagingoftheprimarytumourwasperformed
after every two cycles of docetaxel to assess response.
Following completion of therapy patients were
followed at regular intervals as clinically indicated
and date of progression and/or death recorded.
Treatment plan
Docetaxel was given on an outpatient basis at a dose
of 100mg/m
2 by intravenous infusion over 1h every
21 days for a maximum of six cycles. Dexamethasone
was given as pre-medication, 8mg twice daily
starting 24h before the docetaxel infusion and
continuing for a total of 5 days. When the degree
of myelosuppression became apparent in this group
of heavily pre-treated patients and those in a parallel
phase II study in osteosarcoma, growth factors
(GCSF, Lenograstim236 mg/day for 10 days) were
used to avoid infection and dose reduction.
Toxicity was assessed according to the National
Cancer Institute common toxicity criteria and the
appropriate dose modifications made where indi-
cated. The lowest dose allowed following dose
reduction was 55mg/m
2.
Assessments of clinical response
A complete response was defined as the complete
disappearance of all previously measured tumour for
a period of at least 4 weeks. A partial response (PR)
was defined as a 50% reduction or more in the sum
of the products of two perpendicular diameters of
all measured lesions lasting for at least 4 weeks.
Progressive disease was recorded if there was an
increase in any measurable lesion by 25% or the
appearance of a new lesion. Stable disease was
defined as a response less than PR or the absence
of progression. The duration of response spanned
the time of response to disease progression. Time to
progression and overall survival were measured from
the time of study entry to the time of progression
and death.
Results
Patient characteristics
Fourteen patients aged between 15 and 37 years
(median 23.5) were enrolled on the study between
April 1997 and December 1999 (Table 1). Five
patients had metastases at presentation and all
patients initially received prolonged multi-drug
chemotherapy in addition to local treatment with
surgery and/or radiotherapy. At relapse or progres-
sion all but one had pulmonary disease, four had
local relapse and two had bone disease. Six patients
had at least one trial of further chemotherapy before
receiving docetaxel. The median treatment-free
interval between the last cycle of chemotherapy
and the first cycle of docetaxel was 6 months
(range 1–16).
Response evaluation
A total of 40 cycles of docetaxel was given (median
number of cycles per patient was 2, range 1–6).
Treatment was given at full dose in all patients
except patient 1 who received 75% dose after the first
cycle because of neutropenic sepsis. Overall there
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Docetaxel in Ewing’s tumours 15was one partial response and this was in a patient
with extra-osseous Ewing’s sarcoma of the thigh.
Two patients had stable disease and 11 had disease
progression (Table 1). The two patients with stable
disease had a progression-free interval of 7 and 10
months, while the partial response was sustained for
2 months. The median survival of all patients was
5 months (range 2–20).
Toxicity evaluation
The major toxicity was myelosuppression, with five
patients (36%) experiencing grade 3 or 4 neutro-
penia and five (36%) experiencing grade 3 infection
(Table 2). GCSF was given in 27 out of 41 cycles of
chemotherapy (66%). Nine patients who had pre-
viously received high dose chemotherapy or multiple
previous courses of chemotherapy were treated with
GCSF fromcycle one onwards. Grade 3 or 4
neutropenia was recorded in six of 27 (22%) cycles
in which GCSF was given and in two of 14 (14%)
cycles in which it was not. Mild anaemia was also
common with 11 (79%) patients developing grade 1
or 2 anaemia and one patient developing grade 3
anaemia. Thrombocytopenia only occurred in three
patients. One patient experienced grade 3 stomatitis
but this was the only non-haematological toxicity
greater than grade 2. Other toxicities recorded at
grade 1 and 2 included arthralgia (42%), stomatitis
(35%), myalgia and nausea (both 28%), lethargy and
rash (both 21%) and neuropathy, constipation and
headache (all 14%). There were no episodes of
vomiting or anaphylaxis and no toxic deaths. Further-
more, no patient withdrew from study because of
toxicity and out of the 40 cycles given only seven
were delayed for a median of 7 days (range 1–15).
Discussion
In this study we have evaluated the efficacy and
toxicity of docetaxel in patients with Ewing’s
tumours that have progressed or recurred after
prior treatment. Docetaxel was given according to
the standard dose and schedule used effectively in
other tumours.
13 The patients had all been heavily
pre-treated with multi-drug chemotherapy and four
patients had received high dose myeloablative
chemotherapy as part of their primary treatment,
while a further patient received high dose treatment
as part of relapse therapy. Furthermore six patients
had received at least one trial of relapse chemother-
apy. In short, this was a very heavily pre-treated
group. In spite of this, one patient achieved a partial
response and two had disease stabilisation. As anti-
cipated, myelosuppression was the major toxicity,
but the drug was otherwise well tolerated and no
patient withdrew fromthe study because of unac-
ceptable toxicity.
There are very few published data examining the
efficacy of docetaxel in Ewing’s tumours. In a phase I
trial, performed in children with a variety of refrac-
tory solid tumours, one partial response and two
minimal responses were seen in three patients with
peripheral primitive neuroectodermal tumours.
22
Our study therefore represents the first systematic
analysis of docetaxel in this rare disease. The number
of patients treated is small and insufficient to provide
an accurate response rate, but it is unlikely that
docetaxel has a role in heavily pre-treated patients.
Nevertheless, its activity needs to be further defined
at an earlier stage in the disease. Many drugs have
been found to be effective as first line treatments
while showing little activity in heavily pre-treated
patients. Topotecan, for example was ineffective
when used in pre-treated patients with rhabdomyo-
sarcoma
23 but gave response rates of 45% as first
line treatment.
24 If docetaxel has a role in Ewing’s
tumours it is likely to be as part of sequential or
multi-drug chemotherapy. Data regarding its use in
multi-drug regimens is limited, but it has been safely
combined with other drugs used in the treatment of
Ewings tumours such as doxorubicin,
25,26 suggesting
that such combinations are feasible.
Other investigators have reported myelosuppres-
sion as the major toxicity of docetaxel and some
have suggested that the dose should be lowered to
75mg/m
2.
27 However, the use of GCSF in our group
of patients allowed us to maintain full dose treatment
in all but one patient and we would recommend a
dose of 100mg/m
2 for further studies.
In summary, docetaxel appears to be reasonably
tolerated and have some activity in Ewing’s tumours.
Its role needs to be further evaluated earlier in the
disease to determine its efficacy in less heavily pre-
treated patients. A phase II window study in patients
presenting with metastatic disease would be an
appropriate setting to pursue this question.
Table 2. Treatment-related toxicity
Toxicity Patients with toxicity grade
1234
White blood count 2332
Neutropenia 2214
Anaemia 7 4 1
Thrombocytopenia 2 1
Arthralgia 3 3
Lethargy 1 2
Myalgia 2 2
Nausea 4
Stomatitis 3 1 1
Infection 7 5
Rash 2 1
Neuropathy 2
Constipation 2
Headache 2
The worst grade of toxicity experienced for a given side
effect during the entire course of chemotherapy was
recorded for each patient and the number of patients
reporting this grade is shown in the table.
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